The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients
Status:
Terminated
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is determine the interaction of eslicarbazepine acetate (ESL, BIA
2-093) on the steadystate pharmacokinetics of phenytoin in patients and to evaluate the
tolerability and safety of ESL administered concomitantly with phenytoin in patients.